Trial Profile
Safety and P2Y12 Receptor Inhibition Effects of Ticagrelor and Clopidogrel in Vietnamese Patients With Coronary Heart Disease: A Randomized, Open Label, Crossover Study
Status:
Withdrawn prior to enrolment
Phase of Trial:
Phase III
Latest Information Update: 07 Nov 2021
Price :
$35
*
At a glance
- Drugs Clopidogrel (Primary) ; Ticagrelor (Primary)
- Indications Coronary artery disease; Thrombosis
- Focus Pharmacodynamics
- 01 Apr 2013 Status changed from not yet recruiting to withdrawn prior to recruitment as reported by ClinicalTrials.gov record.
- 22 Jan 2013 New trial record